CLBS Caladrius Biosciences Inc.

2.32
+0.01  (+0%)
Previous Close 2.31
Open 2.34
Price To Book 0.81
Market Cap 24,131,874
Shares 10,401,670
Volume 5,420
Short Ratio
Av. Daily Volume 15,010
Stock charts supplied by TradingView

NewsSee all news

  1. Caladrius Biosciences to Participate at the Upcoming October Conferences

    BASKING RIDGE, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  2. Caladrius Biosciences to Participate at the Upcoming September Conferences

    BASKING RIDGE, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data did not meet primary endpoint - February 13, 2019.
CLBS03 (The Sanford Project T-Rex Study)
Type 1 diabetes
Announced January 2016 that Phase 3 trial has been discontinued
CLBS20
Metastatic melanoma
Phase 2 data due 1Q 2020.
CLBS16 (CLBS14-CMD) - ESCaPE-CMD
Coronary microvascular dysfunction (CMD)
Phase 3 trial to be initiated in early 2020.
CLBS14-NORDA
Angina
Phase 2 data due 2H 2020.
CLBS12
Critical Limb Ischemia (CLI)

Latest News

  1. Caladrius Biosciences to Participate at the Upcoming October Conferences

    BASKING RIDGE, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements

  2. Caladrius Biosciences to Participate at the Upcoming September Conferences

    BASKING RIDGE, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company pioneering advancements